The Lancet Oncology, Volume 14, Issue 2
, Page e47, February 2013
doi:10.1016/S1470-2045(13)70029-9Cite or Link Using DOI
Copyright © 2013 Elsevier Ltd All rights reserved.
Correction to Lancet Oncol 2013; 14: 88, 89, 95
Goss PE, Smith IE, O'Shaughnessy J, et al, on behalf of the TEACH investigators. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 88—96—The second sentence of the Methods in the Summary should read “Women outpatients from 405 centres in 33 countries with HER2-positive early-breast cancer who had previously received adjuvant chemotherapy but not trastuzumab were randomly assigned (1:1) to receive daily lapatinib (1500 mg) or daily placebo for 12 months”, and the second sentence of the Study design and participants section, should read “Participants were hospital outpatients at 405 centres in 33 countries worldwide”. Also, page 95, lines 18—19 should read “…judged this group futile in terms of its non-inferiority over trastuzumab”. The online version was corrected on Jan 28, 2013.